Evidence map›Paper›PMID 40205476›Full record

ArticleCancer & metabolism2025

Ketomimetic nutrients remodel the glycocalyx and trigger a metabolic defense in breast cancer cells.

Mohini Kamra, Yuan-I Chen, Paula C Delgado, Erin H Seeley, Stephanie K Seidlits, Hsin-Chih Yeh, Amy Brock, Sapun H Parekh

Abstract read
In one paragraph

Article in Cancer & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mohini KamraDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, 78712, USA. mkamra@utexas.edu.
Yuan-I ChenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, 78712, USA.
Paula C DelgadoDepartment of Metallurgical, Materials, and Biomedical Engineering, University of Texas at El Paso, El Paso, TX, 79968, USA.
Erin H SeeleyDepartment of Chemistry, University of Texas at Austin, Austin, TX, 78712, USA.
Stephanie K SeidlitsDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, 78712, USA.
Hsin-Chih YehDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, 78712, USA.
Amy BrockDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, 78712, USA.
Sapun H ParekhDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, 78712, USA. sparekh@utexas.edu.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Using label-free Raman microscopy to predict therapeutic resistance of TNBC cellsU01CA253540 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI BROCK, AMY, YANKEELOV, THOMAS E · 2020 to 2024
$2.1M
Tissue-Engineered Models of Microvessel-Mediated Glioblastoma InvasionR01CA241927 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI SEIDLITS, STEPHANIE KRISTIN · 2020 to 2024
$1.9M
Studying synaptic transmission under opioid exposure using hiPSC-derived midbrain model and hyperspectral fluorescence lifetime imagingR21DA060543 · NIDA · UNIVERSITY OF TEXAS AT AUSTIN · PI SEIDLITS, STEPHANIE KRISTIN, YEH, HSIN-CHIH · 2024 to 2025
$404k
Cancer Prevention and Research Institute of Texas RP190617National Science Foundation CBET2432379NCI NIH HHS 75N91019D00024NCI NIH HHS R01 CA241927NCI NIH HHS U01 CA253540NIH HHS Contract No.75N91019D00024NIH HHS R01CA241927NIH HHS R21DA060543NIH HHS U01CA253540-04S2Welch Foundation F-2008-20220331
6 · The paper itself

Abstract

backgroundWhile the triggers for the metastatic transformation of breast cancer (BC) cells remain unknown, recent evidence suggests that intrinsic cellular metabolism could be a crucial driver of migratory disposition and chemoresistance. Aiming to decipher the molecular mechanisms involved in BC cell metabolic maneuvering, we study how a ketomimetic (ketone body-rich, low glucose) nutrient medium can engineer the glycocalyx and metabolic signature of BC cells, to further maneuver their response to therapy.

methodsDoxorubicin (DOX) has been used as a model chemotherapeutic in this study. Bioorthogonal imaging was used to assess the degree of sialylation of the glycocalyx along with measurements of drug-induced cytotoxicity and drug internalization. Single cell label-free metabolic imaging has been performed, coupled with measurement of cellular proliferative and migratory abilities, and MS-based metabolomic screens. Transcriptomic analysis of crucial enzymes was performed using total RNA extraction and rt-qPCR.

resultsWe found an inverse correlation of glycocalyx sialylation with drug-induced cytotoxicity and drug internalization, where ketomimetic media enhanced sialylation and protected BC cells from DOX. These hypersialylated cells proliferated slower and migrated faster as compared to their counterparts receiving a high glucose media, while exhibiting a preference for glycolysis. These cells also showed pronounced lipid droplet accumulation coupled with an inversion in their metabolomic profile. Enzymatic removal of sialic acid moieties at the glycocalyx revealed for the first time, a direct role of sialic acids as defense guards, blocking DOX entry at the cellular membrane to curtail internalization. Interestingly, the non-cancerous mammary epithelial cells exhibited opposite trends and this differential pattern in cancer vs. normal cells was traced to its biochemical roots, i.e. the expression levels of key enzymes involved in sialylation and fatty acid synthesis.

conclusionsOur findings revealed that a ketomimetic medium enhances chemoresistance and invasive disposition of BC cells via two main oncogenic pathways: hypersialylation and lipid synthesis. We propose that the crosstalk between these pathways, juxtaposed at the synthesis of the glycan precursor UDP-GlcNAc, furthers advancement of a metastatic phenotype in BC cells under ketomimetic conditions. Non-cancerous cells lack this dual defense machinery and end up being sensitized to DOX under ketomimetic conditions.

Indexed as

Breast cancer metabolismGlycocalyx engineeringHypersialylationKetogenic dietKetomimeticLipid metabolism

Identifiers

PMID40205476
PMCPMC11984013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.